Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Lupus Nephritis

ClinicalTrials.gov lists 330 trials for Lupus Nephritis or a narrower condition beneath it. Novartis Pharmaceuticals has the most among industry and government lead sponsors, with 10.

MeSH D008181 Urogenital Diseases C12 C17 C20
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 50 Phase 1/2 Phase 1/2 30 Phase 2 Phase 2 65 Phase 2/3 Phase 2/3 5 Phase 3 Phase 3 47 Phase 4 Phase 4 29 Not applicable Not applicable 32 Observational Observational 72 Phase 1 Phase 1 50 Phase 1/2 Phase 1/2 30 Phase 2 Phase 2 65 Phase 2/3 Phase 2/3 5 Phase 3 Phase 3 47 Phase 4 Phase 4 29 Not applicable Not applicable 32 Observational Observational 72

Trials per phase

330 of the 330 trials are tagged with Lupus Nephritis itself; the rest are tagged with a narrower condition beneath it.

Get the Lupus Nephritis report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Lupus Nephritis trials start? (30)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 1 trial is registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational

Top of scale: 35

1994: 1 trials (Observational 1) 1996: 1 trials (Observational 1) 1998: 1 trials (Phase 1 1) 1999: 1 trials (Phase 2 1) 2001: 2 trials (Observational 1, Phase 3 1) 2002: 3 trials (Phase 2/3 1, Phase 2 2) 2003: 3 trials (Phase 3 1, Phase 1/2 1, Phase 1 1) 2004: 4 trials (Not applicable 1, Phase 4 1, Phase 3 1, Phase 1/2 1) 2005: 4 trials (Not applicable 1, Phase 4 1, Phase 3 2) 2006: 5 trials (Phase 3 3, Phase 2/3 1, Phase 2 1) 2007: 7 trials (Observational 1, Phase 3 1, Phase 2/3 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 2008: 7 trials (Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 2, Phase 1/2 1, Phase 1 1) 2009: 4 trials (Not applicable 3, Phase 3 1) 2010: 9 trials (Observational 1, Not applicable 2, Phase 4 3, Phase 3 1, Phase 2 2) 2011: 9 trials (Observational 1, Not applicable 1, Phase 4 1, Phase 3 4, Phase 2 1, Phase 1 1) 2012: 10 trials (Observational 3, Not applicable 2, Phase 3 2, Phase 2/3 1, Phase 2 2) 2013: 9 trials (Observational 5, Phase 4 1, Phase 3 1, Phase 2 2) 2014: 10 trials (Observational 2, Not applicable 1, Phase 4 1, Phase 3 2, Phase 2 2, Phase 1 2) 2015: 10 trials (Observational 1, Phase 4 1, Phase 3 3, Phase 2 5) 2016: 3 trials (Not applicable 1, Phase 2 2) 2017: 10 trials (Observational 2, Not applicable 5, Phase 3 1, Phase 2 1, Phase 1 1) 2018: 12 trials (Observational 4, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2 4, Phase 1/2 1) 2019: 14 trials (Observational 6, Phase 4 3, Phase 3 1, Phase 2 3, Phase 1 1) 2020: 9 trials (Observational 4, Phase 4 1, Phase 3 2, Phase 2 2) 2021: 16 trials (Observational 7, Not applicable 1, Phase 4 1, Phase 3 1, Phase 2/3 1, Phase 2 3, Phase 1/2 1, Phase 1 1) 2022: 24 trials (Observational 3, Not applicable 2, Phase 4 4, Phase 3 6, Phase 2 5, Phase 1/2 1, Phase 1 3) 2023: 23 trials (Observational 3, Phase 4 2, Phase 3 3, Phase 2 8, Phase 1/2 5, Phase 1 2) 2024: 35 trials (Observational 11, Not applicable 2, Phase 4 2, Phase 3 1, Phase 2 2, Phase 1/2 6, Phase 1 11) 2025: 35 trials (Observational 5, Not applicable 1, Phase 4 1, Phase 3 2, Phase 2 4, Phase 1/2 5, Phase 1 17)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 45
2025 35
2024 35
2023 23
2022 24
2021 16
2020 9
2019 14
2018 12
2017 10

Showing 10 of 30 earlier years.

Start your 14-day trial Email me all 30 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 54 trials starting in 2026 and about 43 in 2027, the average of the 24 months through September, counted as registered and carried forward, with about 0.7 times the starts already registered for the rest of 2026 added. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 15 percent and ran about 1 percent high against the count later registered; forecasts made before the year began were off by about 26 percent and ran about 20 percent low against the count later registered. The part-way figures are from forecasts that used a multiple fitted only on earlier years. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 64 trials still running at the 2026-10-09 snapshot; registered median of 30 months across 129 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Lupus Nephritis trials in? (8)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 50
Phase 1/2 30
Phase 2 65
Phase 2/3 5
Phase 3 47
Phase 4 29
Not applicable 32
Observational 72

How many Lupus Nephritis trials are recruiting? (8)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 30
Recruiting 80
Enrolling by invitation 4
Active, not recruiting 15
Completed 96

Showing 5 of 8 statuses.

Start your 14-day trial Email me all 8 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Lupus Nephritis trials? (6)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
Novartis Pharmaceuticals 10
Aurinia Pharmaceuticals Inc. 8
Hoffmann-La Roche 7
National Institute of Allergy and Infectious Diseases (NIAID) 5
China Immunotech (Beijing) Biotechnology Co., Ltd. 4

Showing 5 of 6 sponsors.

Start your 14-day trial Email me all 6 sponsors as a PDF

Which drugs are being tested for Lupus Nephritis? (8)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 39
RITUXIMAB 12
Voclosporin 11
Prednisone 11
METHYLPREDNISOLONE 8

Showing 5 of 8 drugs.

Start your 14-day trial Email me all 8 drugs as a PDF

Interventions as named in the registry (7)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Mofetil Mycophenolate 30
IR Tacrolimus 15
SQ Fludarabine 14
Azathioprine Pill 11
Corticosteroids 4

Showing 5 of 7 interventions.

Start your 14-day trial Email me all 7 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Lupus Nephritis trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Pneumonia 144 23
Lupus nephritis 71 16
Systemic lupus erythematosus 63 15
Herpes zoster 55 15
Gastroenteritis 47 19

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Lupus Nephritis? (250)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Predictors of renal flares in systemic lupus erythematosus: a post-hoc analysis of four phase III clinical trials of belimumab. Rheumatology (Oxford, England) 2025 Yes
Efficacy and safety of guselkumab in patients with active lupus nephritis: results from a phase 2, randomized, placebo-controlled study. Rheumatology (Oxford, England) 2025 Yes
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. The New England journal of medicine 2025 Yes
Mizoribine or Cyclophosphamide for Lupus Nephritis: A Randomized Clinical Trial. JAMA network open 2025 Yes
2024 American College of Rheumatology (ACR) Guideline for the Screening, Treatment, and Management of Lupus Nephritis. Arthritis & rheumatology (Hoboken, N.J.) 2025 Yes

Showing 5 of 250 publications.

Start your 14-day trial Email me the first 50 publications as a PDF

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence, rare-disease identity, and sub-conditions in mesh.

Browse all condition evidence pages